Reference : Interest of lasofoxifene in the treatment of osteoporosis. Evaluation of "Lasofoxifene i...
Scientific journals : Article
Human health sciences : General & internal medicine
http://hdl.handle.net/2268/87069
Interest of lasofoxifene in the treatment of osteoporosis. Evaluation of "Lasofoxifene in postmenopausal women with osteoporosis". N Engl J Med 2010;362:686-96.
English
Reginster, Jean-Yves mailto [Université de Liège - ULg > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé >]
2010
Expert Opinion on Pharmacotherapy
Ashley Publications Ltd
11
10
1773-5
Yes (verified by ORBi)
International
1465-6566
1744-7666
London
United Kingdom
[en] Lasofoxifene, a new selective estrogen receptor modulator (SERM), was investigated to assess its efficacy and safety in the management of postmenopausal osteoporosis. A dose of 0.5 mg/day of lasofoxifene, given to postmenopausal women with osteoporosis, induced a reduction in vertebral fracture rates after 3 years and a reduction, after 5 years, of nonvertebral fractures, estrogen receptor-positive and invasive breast cancers, major coronary heart diseases and strokes. However, this dose was associated with significant side effects including venous thromboembolisms, pulmonary embolisms, leg cramps, hot flushes, uterine polyps, endometrial hypertrophy, arthralgia and vaginal candidiasis. Since no effect was evidenced on hip fractures, the risk-benefit ratio of this new medication, compared with previously marketed SERMs is, at best, uncertain.
http://hdl.handle.net/2268/87069
10.1517/14656561003785755

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Interest of lasofoxifene in the treatment of osteoporosis. Evaluation of Lasofoxifene in postmenopausal women with osteoporosis.pdfPublisher postprint172.41 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.